ClinicalTrials.Veeva

Menu

Comparative Study of CPC+Zn Mouthwash, Dental Floss, and Essential Oils Mouthwash on Plaque and Gingivitis Reduction (PGMWI)

Colgate-Palmolive logo

Colgate-Palmolive

Status and phase

Completed
Phase 3

Conditions

Plaque Induced Gingival Disease
Gingival Bleeding
Gingivitis and Periodontal Diseases

Treatments

Drug: Toothpaste
Device: Toothbrush
Device: Dental floss
Drug: Essential oils mouthrinse
Drug: Mouthwash CPC+Zn+F

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06607263
CRO-2024-08-PG-MWI-BZ-CB

Details and patient eligibility

About

Clinical study evaluating the effectiveness of an alcohol-free mouthwash containing CPC+Zn compared to dental flossing and an essential oils-containing alcohol mouthwash in reducing dental plaque and gingivitis. This is a Phase III, single-center, double-blind trial with a parallel design. It involves 120 participants aged between 18 and 65, randomized into different groups, and spans 12 weeks.

Full description

This clinical study aims to evaluate the efficacy of an alcohol-free mouthwash containing CPC (Cetylpyridinium Chloride) and Zinc (Zn) in reducing dental plaque and gingivitis compared to dental flossing and a mouthwash with essential oils in an alcohol base. It is a Phase III, randomized, double-blind, parallel-group trial involving 120 participants aged 18 to 65. Subjects will be divided into three groups-one using the CPC+Zn mouthwash, another using the essential oils mouthwash, and a control group using dental floss. Each group will also use a fluoride toothpaste and a soft-bristle toothbrush twice daily over 12 weeks. The primary efficacy variable is the reduction of gingival inflammation also Probing Depth, Bleeding on Probing, and a Plaque Index will be accessed. Subjects will undergo baseline, 4-week, and 12-week evaluations, with data analyzed using ANCOVA to assess the efficacy and safety of the products. Adverse events and compliance will be closely monitored, with strict confidentiality maintained for all participants. The study rigorous design aims to provide comprehensive insights into the effectiveness of these oral hygiene regimens.

Enrollment

120 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Availability for the duration of the study;
  • Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study. Examples include heart problems, valve/hip replacements, etc);
  • Willingness to provide information related to their medical history;
  • ≥20 teeth with scorable facial and lingual surfaces; evidence of gingivitis;
  • ≥10 bleeding sites based on the BI
  • Initial mean gingivitis index of at least 1.5 as determined by the use of the Modified Gingival Index (MGI).
  • Subjects without allergies to the products that are being tested;
  • Informed Consent Form signed.

Exclusion criteria

  • That received dental prophylaxis within 1 month prior to the Baseline visit;
  • Need for antibiotics prior to dental treatment; use of antibiotics, anti-inflammatory or anticoagulant therapy during the three months prior to entry into the study;
  • Usage of oral care products containing chemotherapeutic products within 2 weeks prior to Baseline;
  • Use of smokeless tobacco;
  • Any other condition that would make the volunteer inappropriate for the study.
  • Oral pathology, chronic disease, or a history of allergy to testing products;
  • Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study;
  • Subject participating in any other clinical study;
  • Subject pregnant or breastfeeding;
  • Subject allergic to oral care products, personal care consumer products, or their ingredients;
  • Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine);
  • Periodontal treatment 12 months before the beginning of the study;
  • Current smokers and subjects with a history of alcohol or drug abuse;
  • Subjects with orthodontic appliances or presence of fixed or removable prosthodontics dentures that may interfere with the evaluations

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

120 participants in 3 patient groups

CPC + Zn mouthwash + Brushing
Experimental group
Description:
A regimen composing a CPC + Zn mouthwash + Brushing with a fluoride toothpaste and a commercially available toothbrush
Treatment:
Drug: Mouthwash CPC+Zn+F
Device: Toothbrush
Drug: Toothpaste
Essential oils mouthwash + Brushing
Active Comparator group
Description:
A regimen composing a essential oils mouthwash + Brushing with a fluoride toothpaste and a commercially available toothbrush
Treatment:
Drug: Essential oils mouthrinse
Device: Toothbrush
Drug: Toothpaste
Flossing + Brushing
Active Comparator group
Description:
A regimen composing flossing + Brushing with a fluoride toothpaste and a commercially available toothbrush
Treatment:
Device: Dental floss
Device: Toothbrush
Drug: Toothpaste

Trial contacts and locations

1

Loading...

Central trial contact

Juliano Cavagni, PhD; Cassiano K Rosing, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems